By K. Vivek Mob: 09820310487 Email: email@example.com
Lasa Supergenerics Limited listed on the premier stock exchanges with Mr. Omkar P. Herlekar (Chairman and Managing Director, LASA Supergenrics Ltd.) ringing the bell at a glittering function at NSE in the presence of Mr. Shivanand G. Hegde (Whole Time Director, Lasa Supergenerics Ltd.) and Mr. Hitesh D. Wadhwani (Company Secretary, Lasa Supergenerics Ltd.).
Lasa Group (‘Lasa‘) is a vertically integrated group spanning the entire veterinary, animal and human healthcare value chain—from discovery-to-delivery, with established credentials in research, manufacturing and global marketing. Lasa group is a veterinary API manufacturing entity, which was acquired in April 2012 as a 100 per cent subsidiary by Omkar Speciality Chemicals Limited (OSCL).
Mr. Omkar P. Herlekar, Chairman and Managing Director, LASA Supergenrics Ltd., said, “We started our journey 3 decades ago as a family business and eventually our flagship company Omkar Speciality got listed in 2010. We acquired LASA almost immediately post that with its mother unit in Mahad. LASA was a micro unit at that time manufacturing just two products in veterinary range with annual revenue of just 1 crore rupees. Today after just five years of Lasa’s takeover, the Company has a Rs. 200 crore revenue model. We aspire to grow at 22-25% CAGR. Looking ahead LASA is determined to achieve its goal of becoming a leading force in veterinary healthcare. The objective on which the group was founded have always inspired sustainable growth through innovations in the last 4 years and shall continue to do the same in times to come.”
The vet market is growing at 15%. There was no visible player practicing multistep catalyst chemistry. Less than 20% of products were protected by patents. No visible player had strong R&D capabilities with pipeline focused on high entry barrier products. Very few players had regulatory concerns for developed market like Australia, Europe and Latin.
“At Lasa, we have no product dependency and 80% revenue through seven products. We have no customer depending biggest customer is just 3% of revenue. Fully backward integrated each product starts from basic petrochemical. There is no dependency on imports and we practice complex catalyst chemistry brings down raw material cost. Our focus is reducing production time, curtails on effluent output. Envisaging prospective growth potential in vet business and subsequent humongous demand for vet medicine, LASA decided to create complex entry barriers in its business,” said Mr. Herlekar.
“As we begin a new chapter in our illustrious history, we have a responsibility to create value for stakeholders and shareholders. We shall adhere to requisite corporate governance practices and incorporate best in class sustainability measure,” said Mr. Herlekar.
The manufacturing base of Lasa group is located at Mahad, in the Konkan region of Maharashtra. It specialises in ‘catalyst chemistry‘ and manufactures anthelmintic/ veterinary API products with one of the largest production capabilities and product categories in India. To efficiently control the supply chain, the group backward integrated its key molecule from discovery research up to full-scale bulk production.
Lasa’s fully backward integrated API manufacturing model has helped lower product cost. Besides, extensive use of catalysts in API manufacturing process has helped in increase gross profit margins. Similarly, number of catalyst process IPR has prohibited peers from infringing in to process, thereby creating strong entry barriers in business. Further, strong regularity norms for Benzimidazole derivatives offer the Company an edge over competitors.
Lasa has carved its niche in backward integration it is manufacturing process using catalysts. The company uses basic petrochemical derivatives to develop basic organic molecule, basic intermediate to advanced intermediate, N-1 to API products. It has helped in considerably reducing time, decreasing labour costs, cutting down on time cycle, increasing yield and productivity in the same infrastructure thereby increasing EBITDA & gross profit margins, reducing cost of raw materials by mitigating dependency on import, reducing electricity, coal & energy consumption, reducing wear & tear of machines, producing less emission and effluent discharge, and curtailing toxic threshold concentration in effluents, significantly.
The Company‘s Veterinary API manufacturing business is the bedrock for the formulations business of various global companies as it ensures ceaseless supply of key input materials to the formulation manufacturing plants in a timely and cost-efficient manner, thereby enabling them to serve customers in different markets, efficiently.
Lasa group‘s marketing footprint is entrenched across developing markets, such as Australia, Brazil, Canada, China, Colombia, Egypt, Europe, Germany, Hungary, Jordan, Kenya, Korea, Malaysia, Peru, Russia, Saudi Arabia, South Africa, South America, Thailand, Turkey, Uganda, Urugway, USA, Vietnam and West Indies. Similarly, the group expects to augment its export footprint significantly in width and depth in the future.
The group has alliances with leading Indian and global animal healthcare conglomerates, and uses Good Manufacturing Practice (GMP) and world-class technologies in its operations.
Lasa group is managed by a consortium of technocrats, including its Chairman & Managing Director, Mr. Omkar P. Herlekar, who are impelled by passion and propelled by niche innovation. Its leadership team, which is guided by these values, is well positioned to lead the group into the future.
Looking ahead, Lasa group is determined to achieve its goal of becoming a leading force in the niche animal health care solutions. The objective on which the group was founded has always inspired sustainable growth through innovation in the last four years, and shall continue to do so in times to come.